These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8274619)

  • 1. The economic impact and cost-effectiveness of monoclonal antibody therapy for sepsis.
    Chalfin DB; Fein AM
    Clin Infect Dis; 1993 Nov; 17 Suppl 2():S520-4. PubMed ID: 8274619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients.
    Chalfin DB; Holbein ME; Fein AM; Carlon GC
    JAMA; 1993 Jan; 269(2):249-54. PubMed ID: 8417245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide.
    Fink MP
    Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic impact of HA-1A (Centoxin) against endotoxin.
    Barriere SL
    Pharmacoeconomics; 1992 Nov; 2(5):408-13. PubMed ID: 10147053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.
    Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J
    JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.
    Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of HA-1A treatment for patients with sepsis.
    van Hout BA; Birnie E; Redekop WK; Lorijn RH; Bossuyt PM; Rutten FF
    Prog Clin Biol Res; 1994; 388():435-43. PubMed ID: 7831376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
    Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of immunomodulator therapy in sepsis.
    Caplan ES
    Am J Surg; 1993 Feb; 165(2A Suppl):20S-25S. PubMed ID: 8438996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies to endotoxin in the management of sepsis.
    Fang KC
    West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent.
    Schulman KA; Glick HA; Rubin H; Eisenberg JM
    JAMA; 1991 Dec; 266(24):3466-71. PubMed ID: 1744962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome].
    Van Hout BA; Rutten FF; Lorijn RH
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):360-4. PubMed ID: 8437635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A cost-efficacy analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
    Badía X; Segú L; García Alonso F; Rovira J
    Med Clin (Barc); 1993 Jan; 100(3):84-9. PubMed ID: 8426499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody.
    Linden PK; Angus DC; Chelluri L; Branch RA
    J Crit Care; 1995 Dec; 10(4):154-64. PubMed ID: 8924965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis].
    van Deventer SJ; van der Linden CJ; Roord JJ; Schellekens H; Schellekens JF
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):334-6. PubMed ID: 8437630
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival in selected patients with gram-negative sepsis after adjunctive therapy with HA-1A.
    van Dissel JT; van Furth R; Compier BA; Feuth HD; Frolich M
    Lancet; 1993 Apr; 341(8850):959-60. PubMed ID: 8096292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.